In an in vivo study, the combined treatment of MMTV-PyMT mice with paclitaxel and anti-CSF1 antibody slowed primary tumor development, reduced development of high-grade carcinomas, and decreased pulmonary metastasis by 85% and increased CD4+ and CD8+ T-cell infiltration in primary tumors. Here, CSF1 is linked to neoplasm.